Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Authors' reply to Jones, Peel, and English.

Haseler C, Crooke R, Haseler T.

BMJ. 2019 Oct 18;367:l6065. doi: 10.1136/bmj.l6065. No abstract available.

PMID:
31628108
2.

Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease.

Helsley RN, Varadharajan V, Brown AL, Gromovsky AD, Schugar RC, Ramachandiran I, Fung K, Kabbany MN, Banerjee R, Neumann CK, Finney C, Pathak P, Orabi D, Osborn LJ, Massey W, Zhang R, Kadam A, Sansbury BE, Pan C, Sacks J, Lee RG, Crooke RM, Graham MJ, Lemieux ME, Gogonea V, Kirwan JP, Allende DS, Civelek M, Fox PL, Rudel LL, Lusis AJ, Spite M, Brown JM.

Elife. 2019 Oct 17;8. pii: e49882. doi: 10.7554/eLife.49882.

3.

Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction.

Chen S, Henderson A, Petriello MC, Romano KA, Gearing M, Miao J, Schell M, Sandoval-Espinola WJ, Tao J, Sha B, Graham M, Crooke R, Kleinridders A, Balskus EP, Rey FE, Morris AJ, Biddinger SB.

Cell Metab. 2019 Sep 19. pii: S1550-4131(19)30495-4. doi: 10.1016/j.cmet.2019.08.021. [Epub ahead of print]

PMID:
31543404
4.

Promoting physical activity to patients.

Haseler C, Crooke R, Haseler T.

BMJ. 2019 Sep 17;366:l5230. doi: 10.1136/bmj.l5230. No abstract available.

PMID:
31530549
5.

Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-O-Methoxyethyl Antisense Oligonucleotide.

Pirie E, Cauntay P, Fu W, Ray S, Pan C, Lusis AJ, Hsiao J, Burel SA, Narayanan P, Crooke RM, Lee RG.

Nucleic Acid Ther. 2019 Oct;29(5):266-277. doi: 10.1089/nat.2019.0797. Epub 2019 Aug 1.

PMID:
31368839
6.

Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Kanter JE, Shao B, Kramer F, Barnhart S, Shimizu-Albergine M, Vaisar T, Graham MJ, Crooke RM, Manuel CR, Haeusler RA, Mar D, Bomsztyk K, Hokanson JE, Kinney GL, Snell-Bergeon JK, Heinecke JW, Bornfeldt KE.

J Clin Invest. 2019 Jul 11;130:4165-4179. doi: 10.1172/JCI127308.

7.

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.

Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST.

Nat Biotechnol. 2019 Jun;37(6):640-650. doi: 10.1038/s41587-019-0106-2. Epub 2019 Apr 29.

PMID:
31036929
8.

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Wu CH, Wang Y, Ma M, Mullick AE, Crooke RM, Graham MJ, Daugherty A, Lu HS.

Biosci Rep. 2019 Jan 11;39(1). pii: BSR20180201. doi: 10.1042/BSR20180201. Print 2019 Jan 31. Review.

9.

Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1.

Pirie E, Ray S, Pan C, Fu W, Powers AF, Polikoff D, Miller CM, Kudrna KM, Harris EN, Lusis AJ, Crooke RM, Lee RG.

PLoS Genet. 2018 Oct 29;14(10):e1007732. doi: 10.1371/journal.pgen.1007732. eCollection 2018 Oct.

10.

Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.

Donner AJ, Bell TA, Greenlee S, Graham MJ, Crooke RM.

Nucleic Acid Ther. 2018 Oct;28(5):297-306. doi: 10.1089/nat.2018.0723. Epub 2018 Aug 22.

PMID:
30133341
11.

Antisense oligonucleotides targeting translation inhibitory elements in 5' UTRs can selectively increase protein levels.

Liang XH, Sun H, Shen W, Wang S, Yao J, Migawa MT, Bui HH, Damle SS, Riney S, Graham MJ, Crooke RM, Crooke ST.

Nucleic Acids Res. 2017 Sep 19;45(16):9528-9546. doi: 10.1093/nar/gkx632.

12.

Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.

Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP, Crooke RM.

Hypertension. 2017 Sep;70(3):566-576. doi: 10.1161/HYPERTENSIONAHA.117.09755. Epub 2017 Jul 17.

PMID:
28716988
13.

The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue.

Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, Brown AL, Gromovsky AD, Heine M, Chatterjee A, Li L, Li XS, Wang Z, Willard B, Meng Y, Kim H, Che N, Pan C, Lee RG, Crooke RM, Graham MJ, Morton RE, Langefeld CD, Das SK, Rudel LL, Zein N, McCullough AJ, Dasarathy S, Tang WHW, Erokwu BO, Flask CA, Laakso M, Civelek M, Naga Prasad SV, Heeren J, Lusis AJ, Hazen SL, Brown JM.

Cell Rep. 2017 Jul 5;20(1):279. doi: 10.1016/j.celrep.2017.06.053. No abstract available.

14.

The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue.

Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, Brown AL, Gromovsky AD, Heine M, Chatterjee A, Li L, Li XS, Wang Z, Willard B, Meng Y, Kim H, Che N, Pan C, Lee RG, Crooke RM, Graham MJ, Morton RE, Langefeld CD, Das SK, Rudel LL, Zein N, McCullough AJ, Dasarathy S, Tang WHW, Erokwu BO, Flask CA, Laakso M, Civelek M, Naga Prasad SV, Heeren J, Lusis AJ, Hazen SL, Brown JM.

Cell Rep. 2017 Jun 20;19(12):2451-2461. doi: 10.1016/j.celrep.2017.05.077. Erratum in: Cell Rep. 2017 Jul 5;20(1):279.

15.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

16.

The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis.

Ferguson D, Zhang J, Davis MA, Helsley RN, Vedin LL, Lee RG, Crooke RM, Graham MJ, Allende DS, Parini P, Brown JM.

J Lipid Res. 2017 Feb;58(2):420-432. doi: 10.1194/jlr.M073734. Epub 2016 Dec 10.

17.

Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice.

Newberry EP, Xie Y, Kennedy SM, Graham MJ, Crooke RM, Jiang H, Chen A, Ory DS, Davidson NO.

Hepatology. 2017 Mar;65(3):836-852. doi: 10.1002/hep.28941. Epub 2017 Jan 19.

18.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
19.

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD.

J Clin Invest. 2016 Aug 1;126(8):2855-66. doi: 10.1172/JCI86610. Epub 2016 Jul 11.

20.

Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require ATGL Co-activation.

Lord CC, Ferguson D, Thomas G, Brown AL, Schugar RC, Burrows A, Gromovsky AD, Betters J, Neumann C, Sacks J, Marshall S, Watts R, Schweiger M, Lee RG, Crooke RM, Graham MJ, Lathia JD, Sakaguchi TF, Lehner R, Haemmerle G, Zechner R, Brown JM.

Cell Rep. 2016 Jul 26;16(4):939-949. doi: 10.1016/j.celrep.2016.06.049. Epub 2016 Jul 7.

21.

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM.

Diabetes Care. 2016 Aug;39(8):1408-15. doi: 10.2337/dc16-0126. Epub 2016 Jun 6.

PMID:
27271183
22.

Angiotensinogen Exerts Effects Independent of Angiotensin II.

Lu H, Wu C, Howatt DA, Balakrishnan A, Moorleghen JJ, Chen X, Zhao M, Graham MJ, Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):256-65. doi: 10.1161/ATVBAHA.115.306740. Epub 2015 Dec 17.

23.

CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation.

Donner AJ, Yeh ST, Hung G, Graham MJ, Crooke RM, Mullick AE.

Mol Ther Nucleic Acids. 2015 Dec 1;4:e265. doi: 10.1038/mtna.2015.40.

24.

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Graham MJ, Viney N, Crooke RM, Tsimikas S.

J Lipid Res. 2016 Mar;57(3):340-51. doi: 10.1194/jlr.R052258. Epub 2015 Nov 4. Review. Erratum in: J Lipid Res. 2016 Dec;57(12 ):2235.

25.

Insulin Dissociates the Effects of Liver X Receptor on Lipogenesis, Endoplasmic Reticulum Stress, and Inflammation.

Sun X, Haas ME, Miao J, Mehta A, Graham MJ, Crooke RM, Pais de Barros JP, Wang JG, Aikawa M, Masson D, Biddinger SB.

J Biol Chem. 2016 Jan 15;291(3):1115-22. doi: 10.1074/jbc.M115.668269. Epub 2015 Oct 28.

26.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ.

N Engl J Med. 2015 Jul 30;373(5):438-47. doi: 10.1056/NEJMoa1400283.

27.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

PMID:
26210642
28.

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.

Miao J, Manthena PV, Haas ME, Ling AV, Shin DJ, Graham MJ, Crooke RM, Liu J, Biddinger SB.

Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1589-96. doi: 10.1161/ATVBAHA.115.305688. Epub 2015 May 28.

29.

Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes.

Åvall K, Ali Y, Leibiger IB, Leibiger B, Moede T, Paschen M, Dicker A, Daré E, Köhler M, Ilegems E, Abdulreda MH, Graham M, Crooke RM, Tay VS, Refai E, Nilsson SK, Jacob S, Selander L, Berggren PO, Juntti-Berggren L.

Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2611-9. doi: 10.1073/pnas.1423849112. Epub 2015 May 4.

30.

Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis.

Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, Croce KJ, Esquejo RM, Clish CB; Morbid Obesity Study Group, Vicent D, Biddinger SB.

Nat Commun. 2015 Apr 7;6:6498. doi: 10.1038/ncomms7498.

31.

The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance.

Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, Marshall S, McDaniel A, Schugar RC, Wang Z, Sacks J, Rong X, Vallim TA, Chou J, Ivanova PT, Myers DS, Brown HA, Lee RG, Crooke RM, Graham MJ, Liu X, Parini P, Tontonoz P, Lusis AJ, Hazen SL, Temel RE, Brown JM.

Cell Rep. 2015 Jan 20;10(3):326-338. doi: 10.1016/j.celrep.2014.12.036. Epub 2015 Jan 15.

32.

Targeting APOC3 in the familial chylomicronemia syndrome.

Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL.

N Engl J Med. 2014 Dec 4;371(23):2200-6. doi: 10.1056/NEJMoa1400284.

33.

Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers.

Noveck R, Stroes ES, Flaim JD, Baker BF, Hughes S, Graham MJ, Crooke RM, Ridker PM.

J Am Heart Assoc. 2014 Jul 10;3(4). pii: e001084. doi: 10.1161/JAHA.114.001084.

34.

Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion.

Marshall SM, Gromovsky AD, Kelley KL, Davis MA, Wilson MD, Lee RG, Crooke RM, Graham MJ, Rudel LL, Brown JM, Temel RE.

PLoS One. 2014 Jun 5;9(6):e98953. doi: 10.1371/journal.pone.0098953. eCollection 2014.

35.

Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits.

Yu Q, Liu Z, Waqar AB, Ning B, Yang X, Shiomi M, Graham MJ, Crooke RM, Liu E, Dong S, Fan J.

Mediators Inflamm. 2014;2014:979132. doi: 10.1155/2014/979132. Epub 2014 Apr 27.

36.

Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models.

Szalai AJ, McCrory MA, Xing D, Hage FG, Miller A, Oparil S, Chen YF, Mazzone M, Early R, Henry SP, Zanardi TA, Graham MJ, Crooke RM.

Mediators Inflamm. 2014;2014:353614. doi: 10.1155/2014/353614. Epub 2014 Apr 2.

37.

Hepatic Mttp deletion reverses gallstone susceptibility in L-Fabp knockout mice.

Xie Y, Fung HY, Newberry EP, Kennedy S, Luo J, Crooke RM, Graham MJ, Davidson NO.

J Lipid Res. 2014 Mar;55(3):540-8. doi: 10.1194/jlr.M046342. Epub 2014 Jan 28.

38.

Reduction of VLDL secretion decreases cholesterol excretion in niemann-pick C1-like 1 hepatic transgenic mice.

Marshall SM, Kelley KL, Davis MA, Wilson MD, McDaniel AL, Lee RG, Crooke RM, Graham MJ, Rudel LL, Brown JM, Temel RE.

PLoS One. 2014 Jan 3;9(1):e84418. doi: 10.1371/journal.pone.0084418. eCollection 2014.

39.

The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome.

Thomas G, Betters JL, Lord CC, Brown AL, Marshall S, Ferguson D, Sawyer J, Davis MA, Melchior JT, Blume LC, Howlett AC, Ivanova PT, Milne SB, Myers DS, Mrak I, Leber V, Heier C, Taschler U, Blankman JL, Cravatt BF, Lee RG, Crooke RM, Graham MJ, Zimmermann R, Brown HA, Brown JM.

Cell Rep. 2013 Oct 31;5(2):508-20. doi: 10.1016/j.celrep.2013.08.047. Epub 2013 Oct 3.

40.

Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.

Crooke RM, Graham MJ.

Methods Mol Biol. 2013;1027:309-24. doi: 10.1007/978-1-60327-369-5_14.

PMID:
23912993
41.

Antisense technology: an emerging platform for cardiovascular disease therapeutics.

Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM.

J Cardiovasc Transl Res. 2013 Dec;6(6):969-80. doi: 10.1007/s12265-013-9495-7. Epub 2013 Jul 16. Review.

42.

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.

Bell TA 3rd, Graham MJ, Lee RG, Mullick AE, Fu W, Norris D, Crooke RM.

J Lipid Res. 2013 Oct;54(10):2647-57. doi: 10.1194/jlr.M036509. Epub 2013 Jun 25.

43.

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.

Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM.

Circ Res. 2013 May 24;112(11):1479-90. doi: 10.1161/CIRCRESAHA.111.300367. Epub 2013 Mar 29.

PMID:
23542898
44.

Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation.

Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ.

Cell Metab. 2013 Jan 8;17(1):49-60. doi: 10.1016/j.cmet.2012.12.011.

45.

Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Lee RG, Fu W, Graham MJ, Mullick AE, Sipe D, Gattis D, Bell TA, Booten S, Crooke RM.

J Lipid Res. 2013 Mar;54(3):602-14. doi: 10.1194/jlr.M029215. Epub 2012 Dec 6.

46.

Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression.

Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, Hirschey M, Vaitheesvaran B, Farese RV Jr, Kurland IJ, Graham M, Crooke R, Foufelle F, Biddinger SB.

Cell Metab. 2012 Jun 6;15(6):873-84. doi: 10.1016/j.cmet.2012.05.002.

47.

Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice.

Carr RM, Patel RT, Rao V, Dhir R, Graham MJ, Crooke RM, Ahima RS.

Am J Physiol Regul Integr Comp Physiol. 2012 Apr 15;302(8):R996-1003. doi: 10.1152/ajpregu.00177.2011. Epub 2012 Feb 29.

48.

Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice.

Newberry EP, Kennedy SM, Xie Y, Luo J, Crooke RM, Graham MJ, Fu J, Piomelli D, Davidson NO.

J Lipid Res. 2012 Apr;53(4):744-54. doi: 10.1194/jlr.M020966. Epub 2012 Feb 10.

49.

Endothelial lipase mediates HDL levels in normal and hyperlipidemic rabbits.

Zhang J, Yu Y, Nakamura K, Koike T, Waqar AB, Zhang X, Liu E, Nishijima K, Kitajima S, Shiomi M, Qi Z, Yu J, Graham MJ, Crooke RM, Ishida T, Hirata K, Hurt-Camejo E, Chen YE, Fan J.

J Atheroscler Thromb. 2012;19(3):213-26. Epub 2012 Jan 12.

50.

CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action.

Lord CC, Betters JL, Ivanova PT, Milne SB, Myers DS, Madenspacher J, Thomas G, Chung S, Liu M, Davis MA, Lee RG, Crooke RM, Graham MJ, Parks JS, Brasaemle DL, Fessler MB, Brown HA, Brown JM.

Diabetes. 2012 Feb;61(2):355-63. doi: 10.2337/db11-0994. Epub 2012 Jan 6.

Supplemental Content

Loading ...
Support Center